OWCP:
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) Sets the Stage for 2017
By Jermaine Farmer - January 27, 2017
SHARE Facebook Twitter
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) is a micro-cap medical marijuana play that has some monster gains under its belt over the past few weeks. And traders have certainly taken notice. Management just hit the wires with its annual letter to the Company’s shareholders to further stoke the flames of enthusiasm for this pre-revenue play.
Perhaps most important to note in the letter were the anticipated action items the company would be looking forward to in 2017: 1. During the second quarter of 2017 OWCP intends to initiate its U.S marketing program for its Psoriasis Topical Cream. At the same time, we intend to begin investigating the applicability of topical cream for other skin conditions and disorders. 2. OWCP intends to proceed with the advancement of our cannabis-based treatment for multiple myeloma, with the objective of proceeding with additional studies. And 3. OWCP intends to evaluate the launch of one or more studies to determine the applicability of cannabinoid-based pharmaceuticals for other medical conditions and disorders, such as fibromyalgia and migraines.
OWC Pharmaceutical Research Corp (OTCMKTS:OWCP) bills itself as a company that engages in the research and development of Cannabis-based medical products. The company provides medical products for the treatment of various medical conditions and/or diseases, such as multiple myeloma, psoriasis, PTSD, and migraines; and delivery systems. It also provides consulting services to companies and governmental agencies related to international medical cannabis protocols and regulations.
OWCP through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals, treatments and unique delivery systems for the effective delivery and dosage of medical cannabis.
All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
The Company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids in the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.
The Company is a wholly owned subsidiary of OWC Pharmaceutical Research Corp. The company was formerly known as Dynamic Applications Corp. OWC Pharmaceutical Research Corp. was founded in 2008 and is based in Petach Tikva, Israel.
According to company materials, “OWC Pharmaceutical Research Corp., through its wholly-owned Israeli subsidiary, One Word Cannabis Ltd., (collectively “OWC” or the “Company”) conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWC is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All OWC research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators. The Company’s Research Division is focused on pursuing clinical trials evaluating the effectiveness of cannabinoids for the treatment of various medical conditions, while its Consulting Division is dedicated to helping governments and companies navigate complex international cannabis regulatory frameworks.”
